Details of the Drug

General Information of Drug (ID: DM35M8J)

Drug Name
Thioridazine
Synonyms
Aldazine; Mallorol; Malloryl; Meleril; Mellaril; Mellarit; Mellerets; Mellerette; Melleretten; Melleril; Melleryl; Metlaril; Novoridazine; Orsanil; Ridazine; Sonapax; Stalleril; Thioridazin; Thioridazinum; Thioxidazine; Tioridazin; Tioridazina; Thioridazine Hcl; Thioridazine Hcl Intensol; Thioridazine prolongatum; Thoridazine hydrochloride; Dl-Thioridazine; Mellaril (TN); Mellaril-S; Melleril (liquid); Novoridazine (TN); TP-21; Thioridazine, prolongatum; Thioridazinum [INN-Latin]; Thioril (TN); Tioridazina [INN-Spanish]; Mellaril-S (TN); Thioridazine (USP/INN); Thioridazine [USAN:INN:BAN]; Mellaril (*Hydrochloride*); (+-)-Thioridazine; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-(methylthio)phenothiazine; 10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylthio)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine; 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine; 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [1], [2]
Therapeutic Class
Antipsychotic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 370.6
Topological Polar Surface Area (xlogp) 5.9
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption
The absorption of drug is 60% [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 21 - 25 hours [5]
Metabolism
The drug is metabolized via the hepatic [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 35.88942 micromolar/kg/day [6]
Water Solubility
The ability of drug to dissolve in water is measured as 1 mg/mL [4]
Chemical Identifiers
Formula
C21H26N2S2
IUPAC Name
10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine
Canonical SMILES
CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC
InChI
InChI=1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3
InChIKey
KLBQZWRITKRQQV-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5452
ChEBI ID
CHEBI:9566
CAS Number
50-52-2
DrugBank ID
DB00679
TTD ID
D0U1OE
VARIDT ID
DR00785
INTEDE ID
DR1581
ACDINA ID
D00672

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Antagonist [7], [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [10]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Schizophrenia
ICD Disease Classification 6A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
P-glycoprotein 1 (ABCB1) DTP P-GP 9.39E-02 1.07E-01 2.80E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 2.40E-01 -3.31E-02 -1.97E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Thioridazine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Quetiapine DM1N62C Major Additive CNS depression effects by the combination of Thioridazine and Quetiapine. Schizophrenia [6A20] [49]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Thioridazine and Mesoridazine. Schizophrenia [6A20] [50]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Thioridazine and Aripiprazole. Schizophrenia [6A20] [51]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Thioridazine and Iloperidone. Schizophrenia [6A20] [52]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Thioridazine and Paliperidone. Schizophrenia [6A20] [52]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Thioridazine and Molindone. Schizophrenia [6A20] [51]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Thioridazine and Thiothixene. Schizophrenia [6A20] [51]
Trifluoperazine DMKBYWI Major Increased risk of prolong QT interval by the combination of Thioridazine and Trifluoperazine. Schizophrenia [6A20] [53]
Risperidone DMN6DXL Major Increased risk of prolong QT interval by the combination of Thioridazine and Risperidone. Schizophrenia [6A20] [52]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Thioridazine and Amisulpride. Schizophrenia [6A20] [52]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Thioridazine and Asenapine. Schizophrenia [6A20] [52]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Thioridazine and Pimozide. Schizophrenia [6A20] [52]
⏷ Show the Full List of 12 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Thioridazine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Thioridazine and Ivosidenib. Acute myeloid leukaemia [2A60] [54]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Thioridazine and Midostaurin. Acute myeloid leukaemia [2A60] [52]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Thioridazine and Idarubicin. Acute myeloid leukaemia [2A60] [52]
Daunorubicin DMQUSBT Major Increased risk of prolong QT interval by the combination of Thioridazine and Daunorubicin. Acute myeloid leukaemia [2A60] [52]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Thioridazine and Arn-509. Acute myeloid leukaemia [2A60] [54]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Thioridazine and Oliceridine. Acute pain [MG31] [54]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Thioridazine and Scopolamine. Addictive disorder [6C50-6C5Z] [51]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Thioridazine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [55]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Thioridazine and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [55]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Thioridazine and Memantine. Alzheimer disease [8A20] [51]
Rivastigmine DMG629M Moderate Antagonize the effect of Thioridazine when combined with Rivastigmine. Alzheimer disease [8A20] [56]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Thioridazine and Metronidazole. Amoebiasis [1A36] [50]
Isosorbide dinitrate DMBI4JG Moderate Additive hypotensive effects by the combination of Thioridazine and Isosorbide dinitrate. Anal fissure/fistula [DB50] [57]
Trimethaphan DMHF4IQ Moderate Additive hypotensive effects by the combination of Thioridazine and Trimethaphan. Aneurysm/dissection [BD50] [58]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Thioridazine and Ivabradine. Angina pectoris [BA40] [54]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Thioridazine and Bepridil. Angina pectoris [BA40] [54]
Amyl nitrite DMJKO05 Moderate Additive hypotensive effects by the combination of Thioridazine and Amyl nitrite. Angina pectoris [BA40] [57]
Nifedipine DMSVOZT Moderate Additive hypotensive effects by the combination of Thioridazine and Nifedipine. Angina pectoris [BA40] [57]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Thioridazine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [52]
Cilostazol DMZMSCT Major Increased risk of prolong QT interval by the combination of Thioridazine and Cilostazol. Arterial occlusive disease [BD40] [52]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Thioridazine and Posaconazole. Aspergillosis [1F20] [52]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Thioridazine and Levalbuterol. Asthma [CA23] [59]
Terbutaline DMD4381 Major Increased risk of prolong QT interval by the combination of Thioridazine and Terbutaline. Asthma [CA23] [60]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Thioridazine and Pirbuterol. Asthma [CA23] [59]
Ephedrine DMMV0KW Moderate Antagonize the effect of Thioridazine when combined with Ephedrine. Asthma [CA23] [61]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Thioridazine and Salbutamol. Asthma [CA23] [62]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Thioridazine and Formoterol. Asthma [CA23] [60]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Thioridazine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [52]
Desipramine DMT2FDC Major Increased risk of prolong QT interval by the combination of Thioridazine and Desipramine. Attention deficit hyperactivity disorder [6A05] [53]
Ofloxacin DM0VQN3 Major Increased risk of prolong QT interval by the combination of Thioridazine and Ofloxacin. Bacterial infection [1A00-1C4Z] [52]
Clarithromycin DM4M1SG Major Increased risk of prolong QT interval by the combination of Thioridazine and Clarithromycin. Bacterial infection [1A00-1C4Z] [52]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Thioridazine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [52]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Thioridazine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [52]
Gemifloxacin DMHT34O Major Increased risk of prolong QT interval by the combination of Thioridazine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [52]
Norfloxacin DMIZ6W2 Major Increased risk of prolong QT interval by the combination of Thioridazine and Norfloxacin. Bacterial infection [1A00-1C4Z] [54]
Levofloxacin DMS60RB Major Increased risk of prolong QT interval by the combination of Thioridazine and Levofloxacin. Bacterial infection [1A00-1C4Z] [52]
Lomefloxacin DMVRH9C Major Increased risk of prolong QT interval by the combination of Thioridazine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [54]
Telithromycin DMZ4P3A Major Increased risk of prolong QT interval by the combination of Thioridazine and Telithromycin. Bacterial infection [1A00-1C4Z] [54]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Thioridazine and Retigabine. Behcet disease [4A62] [54]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Thioridazine and Cariprazine. Bipolar disorder [6A60] [51]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Thioridazine and Loperamide. Bowel habit change [ME05] [63]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Thioridazine and Eribulin. Breast cancer [2C60-2C6Y] [52]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Thioridazine and Bosutinib. Breast cancer [2C60-2C6Y] [52]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Thioridazine when combined with Acetylcholine. Cataract [9B10] [64]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Thioridazine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [54]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Thioridazine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [65]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Thioridazine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [60]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Thioridazine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [59]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Thioridazine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [60]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Thioridazine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [65]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Thioridazine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [60]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Thioridazine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [60]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Thioridazine and Dihydrocodeine. Chronic pain [MG30] [66]
Isoproterenol DMK7MEY Major Increased risk of prolong QT interval by the combination of Thioridazine and Isoproterenol. Conduction disorder [BC63] [60]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Thioridazine and Olopatadine. Conjunctiva disorder [9A60] [67]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Thioridazine and Halothane. Corneal disease [9A76-9A78] [52]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Thioridazine and Propofol. Corneal disease [9A76-9A78] [68]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Thioridazine and Sevoflurane. Corneal disease [9A76-9A78] [52]
Alfentanil DMVO0UB Major Additive CNS depression effects by the combination of Thioridazine and Alfentanil. Corneal disease [9A76-9A78] [69]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Thioridazine and Remifentanil. Corneal disease [9A76-9A78] [69]
Probucol DMVZQ2M Major Increased risk of prolong QT interval by the combination of Thioridazine and Probucol. Coronary atherosclerosis [BA80] [54]
Clofazimine DMEBOFW Major Increased risk of prolong QT interval by the combination of Thioridazine and Clofazimine. Crohn disease [DD70] [54]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Thioridazine and Mifepristone. Cushing syndrome [5A70] [52]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Thioridazine and Pasireotide. Cushing syndrome [5A70] [52]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Thioridazine and Osilodrostat. Cushing syndrome [5A70] [54]
Cyclandelate DMO0R76 Moderate Additive hypotensive effects by the combination of Thioridazine and Cyclandelate. Dementia [6D80-6D8Z] [58]
Sertraline DM0FB1J Major Decreased metabolism of Thioridazine caused by Sertraline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [70]
Trimipramine DM1SC8M Major Increased risk of prolong QT interval by the combination of Thioridazine and Trimipramine. Depression [6A70-6A7Z] [53]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Thioridazine and Cyclobenzaprine. Depression [6A70-6A7Z] [51]
Paroxetine DM5PVQE Major Decreased metabolism of Thioridazine caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [70]
Selegiline DM6034S Moderate Additive CNS depression effects by the combination of Thioridazine and Selegiline. Depression [6A70-6A7Z] [71]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Thioridazine and Isocarboxazid. Depression [6A70-6A7Z] [71]
Escitalopram DMFK9HG Major Decreased metabolism of Thioridazine caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [70]
Tranylcypromine DMGB5RE Moderate Additive hypotensive effects by the combination of Thioridazine and Tranylcypromine. Depression [6A70-6A7Z] [72]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Thioridazine and OPC-34712. Depression [6A70-6A7Z] [51]
Phenelzine DMHIDUE Moderate Additive CNS depression effects by the combination of Thioridazine and Phenelzine. Depression [6A70-6A7Z] [71]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Thioridazine and Clomipramine. Depression [6A70-6A7Z] [53]
Doxepin DMPI98T Major Increased risk of prolong QT interval by the combination of Thioridazine and Doxepin. Depression [6A70-6A7Z] [53]
Maprotiline DMPWB7T Major Increased risk of prolong QT interval by the combination of Thioridazine and Maprotiline. Depression [6A70-6A7Z] [52]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Thioridazine and Esketamine. Depression [6A70-6A7Z] [50]
Nitroglycerin DMQ2491 Moderate Additive hypotensive effects by the combination of Thioridazine and Nitroglycerin. Diabetic foot ulcer [BD54] [57]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Thioridazine and Mepenzolate. Digestive system disease [DE2Z] [55]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Thioridazine and Oxybutynine. Discovery agent [N.A.] [51]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Thioridazine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [52]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Thioridazine and Meclizine. Dizziness and giddiness [MB48] [51]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Thioridazine and Deutetrabenazine. Dystonic disorder [8A02] [52]
Zonisamide DM0DTF7 Major Additive CNS depression effects by the combination of Thioridazine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [73]
Stiripentol DMMSDOY Moderate Decreased metabolism of Thioridazine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [74]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Thioridazine and Phenoxybenzamine. Essential hypertension [BA00] [57]
Nadolol DMW6GVL Moderate Additive hypotensive effects by the combination of Thioridazine and Nadolol. Essential hypertension [BA00] [57]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Thioridazine and Solifenacin. Functional bladder disorder [GC50] [52]
Mirabegron DMS1GYT Major Decreased metabolism of Thioridazine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [70]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Thioridazine and Tolterodine. Functional bladder disorder [GC50] [51]
Pentamidine DMHZJCG Major Increased risk of prolong QT interval by the combination of Thioridazine and Pentamidine. Fungal infection [1F29-1F2F] [52]
Terbinafine DMI6HUW Major Decreased metabolism of Thioridazine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [70]
Ketoconazole DMPZI3Q Major Increased risk of prolong QT interval by the combination of Thioridazine and Ketoconazole. Fungal infection [1F29-1F2F] [52]
Amphotericin B DMTAJQE Moderate Increased risk of ventricular arrhythmias by the combination of Thioridazine and Amphotericin B. Fungal infection [1F29-1F2F] [50]
Phentolamine DMXYJOB Moderate Additive hypotensive effects by the combination of Thioridazine and Phentolamine. Gangrene [MC85] [57]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Thioridazine and Propantheline. Gastric ulcer [DA60] [51]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Thioridazine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [52]
Acetazolamide DM1AF5U Moderate Increased risk of ventricular arrhythmias by the combination of Thioridazine and Acetazolamide. Glaucoma [9C61] [50]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Thioridazine when combined with Pilocarpine. Glaucoma [9C61] [64]
Eplerenone DMF0NQR Moderate Additive hypotensive effects by the combination of Thioridazine and Eplerenone. Heart failure [BD10-BD1Z] [57]
Chlorothiazide DMLHESP Moderate Increased risk of ventricular arrhythmias by the combination of Thioridazine and Chlorothiazide. Heart failure [BD10-BD1Z] [50]
Furosemide DMMQ8ZG Moderate Increased risk of ventricular arrhythmias by the combination of Thioridazine and Furosemide. Heart failure [BD10-BD1Z] [50]
Bumetanide DMRV7H0 Moderate Increased risk of ventricular arrhythmias by the combination of Thioridazine and Bumetanide. Heart failure [BD10-BD1Z] [50]
Hydroflumethiazide DMVPUQI Moderate Increased risk of ventricular arrhythmias by the combination of Thioridazine and Hydroflumethiazide. Heart failure [BD10-BD1Z] [50]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Thioridazine and Procarbazine. Hodgkin lymphoma [2B30] [71]
MK-1439 DM215WE Major Increased metabolism of Thioridazine caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [54]
Delavirdine DM3NF5G Major Decreased metabolism of Thioridazine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [75]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Thioridazine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [54]
Cobicistat DM6L4H2 Major Decreased metabolism of Thioridazine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [70]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Thioridazine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [52]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Thioridazine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [52]
Isosorbide mononitrate DMYLMU0 Moderate Additive hypotensive effects by the combination of Thioridazine and Isosorbide mononitrate. Hydrocephalus [8D64] [57]
Cinacalcet DMCX0K3 Major Decreased metabolism of Thioridazine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [70]
Eprosartan DM07K2I Moderate Additive hypotensive effects by the combination of Thioridazine and Eprosartan. Hypertension [BA00-BA04] [57]
Acebutolol DM0TI4U Moderate Additive hypotensive effects by the combination of Thioridazine and Acebutolol. Hypertension [BA00-BA04] [57]
Moexipril DM26E4B Moderate Additive hypotensive effects by the combination of Thioridazine and Moexipril. Hypertension [BA00-BA04] [57]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Thioridazine and Captopril. Hypertension [BA00-BA04] [57]
Penbutolol DM4ES8F Moderate Additive hypotensive effects by the combination of Thioridazine and Penbutolol. Hypertension [BA00-BA04] [58]
Methyldopa DM5I621 Moderate Additive hypotensive effects by the combination of Thioridazine and Methyldopa. Hypertension [BA00-BA04] [57]
Nebivolol DM7F1PA Moderate Additive hypotensive effects by the combination of Thioridazine and Nebivolol. Hypertension [BA00-BA04] [57]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Thioridazine and Levamlodipine. Hypertension [BA00-BA04] [57]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Thioridazine and TAK-491. Hypertension [BA00-BA04] [57]
Fenoldopam DMFAOKP Moderate Additive hypotensive effects by the combination of Thioridazine and Fenoldopam. Hypertension [BA00-BA04] [57]
Indapamide DMGN1PW Moderate Increased risk of ventricular arrhythmias by the combination of Thioridazine and Indapamide. Hypertension [BA00-BA04] [50]
Trichlormethiazide DMHAQCO Moderate Additive hypotensive effects by the combination of Thioridazine and Trichlormethiazide. Hypertension [BA00-BA04] [58]
Diazoxide DML1538 Moderate Additive hypotensive effects by the combination of Thioridazine and Diazoxide. Hypertension [BA00-BA04] [57]
Perindopril DMOPZDT Moderate Additive hypotensive effects by the combination of Thioridazine and Perindopril. Hypertension [BA00-BA04] [57]
Felodipine DMOSW35 Moderate Additive hypotensive effects by the combination of Thioridazine and Felodipine. Hypertension [BA00-BA04] [57]
Deserpidine DMRH7CV Moderate Additive hypotensive effects by the combination of Thioridazine and Deserpidine. Hypertension [BA00-BA04] [57]
Telmisartan DMS3GX2 Moderate Additive hypotensive effects by the combination of Thioridazine and Telmisartan. Hypertension [BA00-BA04] [57]
Irbesartan DMTP1DC Moderate Additive hypotensive effects by the combination of Thioridazine and Irbesartan. Hypertension [BA00-BA04] [57]
Hydralazine DMU8JGH Moderate Additive hypotensive effects by the combination of Thioridazine and Hydralazine. Hypertension [BA00-BA04] [57]
Lisinopril DMUOK4C Moderate Additive hypotensive effects by the combination of Thioridazine and Lisinopril. Hypertension [BA00-BA04] [57]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Thioridazine and Clevidipine butyrate. Hypertension [BA00-BA04] [57]
Fludrocortisone DMUDIR8 Moderate Increased risk of ventricular arrhythmias by the combination of Thioridazine and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [50]
Givosiran DM5PFIJ Major Decreased metabolism of Thioridazine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [75]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Thioridazine and Belladonna. Infectious gastroenteritis/colitis [1A40] [51]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Thioridazine and Amantadine. Influenza [1E30-1E32] [76]
Berotralstat DMWA2DZ Major Decreased metabolism of Thioridazine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [77]
Propiomazine DMKY8V1 Major Increased risk of prolong QT interval by the combination of Thioridazine and Propiomazine. Insomnia [7A00-7A0Z] [78]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Thioridazine and ITI-007. Insomnia [7A00-7A0Z] [51]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Thioridazine and Polyethylene glycol. Irritable bowel syndrome [DD91] [79]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Thioridazine and Phenolphthalein. Irritable bowel syndrome [DD91] [50]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Thioridazine and Clidinium. Irritable bowel syndrome [DD91] [51]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Thioridazine and Dicyclomine. Irritable bowel syndrome [DD91] [51]
Physostigmine DM2N0TO Moderate Antagonize the effect of Thioridazine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [56]
Glycerol phenylbutyrate DMDGRQO Major Decreased metabolism of Thioridazine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [70]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Thioridazine and Crizotinib. Lung cancer [2C25] [52]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Thioridazine and Porfimer Sodium. Lung cancer [2C25] [80]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Thioridazine and Ceritinib. Lung cancer [2C25] [52]
Dacomitinib DMOH8VY Major Decreased metabolism of Thioridazine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [75]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Thioridazine and Halofantrine. Malaria [1F40-1F45] [50]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Thioridazine and Hydroxychloroquine. Malaria [1F40-1F45] [52]
Primaquine DMWQ16I Major Increased risk of prolong QT interval by the combination of Thioridazine and Primaquine. Malaria [1F40-1F45] [52]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Thioridazine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [52]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Thioridazine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [52]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Thioridazine and Vemurafenib. Melanoma [2C30] [52]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Thioridazine and LGX818. Melanoma [2C30] [52]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Thioridazine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [81]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Thioridazine and Lasmiditan. Migraine [8A80] [82]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Thioridazine and Flibanserin. Mood disorder [6A60-6E23] [83]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Thioridazine and Panobinostat. Multiple myeloma [2A83] [52]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Thioridazine and Thalidomide. Multiple myeloma [2A83] [54]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Thioridazine and Siponimod. Multiple sclerosis [8A40] [50]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Thioridazine and Fingolimod. Multiple sclerosis [8A40] [52]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Thioridazine and Ozanimod. Multiple sclerosis [8A40] [52]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Thioridazine and Romidepsin. Mycosis fungoides [2B01] [52]
Fedratinib DM4ZBK6 Major Decreased metabolism of Thioridazine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [70]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Thioridazine and Dasatinib. Myeloproliferative neoplasm [2A20] [52]
Dextroamphetamine DMMIHVP Moderate Antagonize the effect of Thioridazine when combined with Dextroamphetamine. Narcolepsy [7A20] [61]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Thioridazine and Phenindamine. Nasopharyngitis [CA00] [55]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Thioridazine and Dimenhydrinate. Nausea/vomiting [MD90] [51]
Promethazine DM6I5GR Major Increased risk of prolong QT interval by the combination of Thioridazine and Promethazine. Nausea/vomiting [MD90] [53]
Rolapitant DM8XP26 Major Decreased metabolism of Thioridazine caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [70]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Thioridazine and Cyclizine. Nausea/vomiting [MD90] [51]
Metoclopramide DMFA5MY Major Additive antidopaminergic effects by the combination of Thioridazine and Metoclopramide. Nausea/vomiting [MD90] [84]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Thioridazine and Granisetron. Nausea/vomiting [MD90] [52]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Thioridazine and Dolasetron. Nausea/vomiting [MD90] [52]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Thioridazine and Ondansetron. Nausea/vomiting [MD90] [52]
Bupropion DM5PCS7 Major Decreased metabolism of Thioridazine caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [70]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Thioridazine and Entrectinib. Non-small cell lung cancer [2C25] [54]
Phendimetrazine DM6TS1N Moderate Antagonize the effect of Thioridazine when combined with Phendimetrazine. Obesity [5B80-5B81] [61]
Amfepramone DM9YSNQ Moderate Antagonize the effect of Thioridazine when combined with Amfepramone. Obesity [5B80-5B81] [61]
Lorcaserin DMG6OYJ Major Decreased metabolism of Thioridazine caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [70]
Benzphetamine DMIJATC Moderate Antagonize the effect of Thioridazine when combined with Benzphetamine. Obesity [5B80-5B81] [61]
Dexfenfluramine DMJ7YDS Major Decreased metabolism of Thioridazine caused by Dexfenfluramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [77]
Polythiazide DMCH80F Moderate Increased risk of ventricular arrhythmias by the combination of Thioridazine and Polythiazide. Oedema [MG29] [50]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Thioridazine and Levomethadyl Acetate. Opioid use disorder [6C43] [54]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Thioridazine and Apraclonidine. Optic nerve disorder [9C40] [85]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Thioridazine and Rucaparib. Ovarian cancer [2C73] [52]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Thioridazine and Oxymorphone. Pain [MG30-MG3Z] [69]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Thioridazine and Dezocine. Pain [MG30-MG3Z] [66]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Thioridazine and Flavoxate. Pain [MG30-MG3Z] [51]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Thioridazine and Nalbuphine. Pain [MG30-MG3Z] [69]
Buprenorphine DMPRI8G Major Increased risk of prolong QT interval by the combination of Thioridazine and Buprenorphine. Pain [MG30-MG3Z] [52]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Thioridazine and Hydrocodone. Pain [MG30-MG3Z] [69]
Safinamide DM0YWJC Moderate Additive CNS depression effects by the combination of Thioridazine and Safinamide. Parkinsonism [8A00] [71]
Pergolide DM14MAE Moderate Antagonize the effect of Thioridazine when combined with Pergolide. Parkinsonism [8A00] [86]
Opicapone DM1BKA6 Moderate Additive hypotensive effects by the combination of Thioridazine and Opicapone. Parkinsonism [8A00] [87]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Thioridazine and Rasagiline. Parkinsonism [8A00] [71]
Biperiden DME78OA Moderate Antagonize the effect of Thioridazine when combined with Biperiden. Parkinsonism [8A00] [88]
Levodopa DMN3E57 Moderate Antagonize the effect of Thioridazine when combined with Levodopa. Parkinsonism [8A00] [86]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Thioridazine and Pimavanserin. Parkinsonism [8A00] [52]
Bromocriptine DMVE3TK Moderate Antagonize the effect of Thioridazine when combined with Bromocriptine. Parkinsonism [8A00] [86]
Apomorphine DMX38HQ Major Increased risk of prolong QT interval by the combination of Thioridazine and Apomorphine. Parkinsonism [8A00] [52]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Thioridazine and Macimorelin. Pituitary gland disorder [5A60-5A61] [89]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Thioridazine and Lefamulin. Pneumonia [CA40] [54]
Hydrocortisone DMGEMB7 Moderate Increased risk of ventricular arrhythmias by the combination of Thioridazine and Hydrocortisone. Postoperative inflammation [1A00-CA43] [50]
Ritodrine DM4V6RL Major Increased risk of prolong QT interval by the combination of Thioridazine and Ritodrine. Preterm labour/delivery [JB00] [60]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Thioridazine and Degarelix. Prostate cancer [2C82] [52]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Thioridazine and Enzalutamide. Prostate cancer [2C82] [52]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Thioridazine and Relugolix. Prostate cancer [2C82] [52]
Bicalutamide DMZMSPF Major Increased risk of prolong QT interval by the combination of Thioridazine and Bicalutamide. Prostate cancer [2C82] [52]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Thioridazine and Terazosin. Prostate hyperplasia [GA90] [57]
Tamsulosin DM5QF9V Moderate Additive hypotensive effects by the combination of Thioridazine and Tamsulosin. Prostate hyperplasia [GA90] [57]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Thioridazine and Silodosin. Prostate hyperplasia [GA90] [57]
Levomepromazine DMIKFEL Major Increased risk of prolong QT interval by the combination of Thioridazine and Levomepromazine. Psychotic disorder [6A20-6A25] [78]
Tolazoline DMI40NL Moderate Additive hypotensive effects by the combination of Thioridazine and Tolazoline. Pulmonary hypertension [BB01] [58]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Thioridazine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [54]
Neupro DMHEAB1 Moderate Antagonize the effect of Thioridazine when combined with Neupro. Restless legs syndrome [7A80] [86]
Oxamniquine DM2QDX1 Major Decreased metabolism of Thioridazine caused by Oxamniquine mediated inhibition of CYP450 enzyme. Schistosomiasis [1F86] [77]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Thioridazine and Fentanyl. Sensation disturbance [MB40] [69]
Sufentanil DMU7YEL Major Additive CNS depression effects by the combination of Thioridazine and Sufentanil. Sensation disturbance [MB40] [69]
Vardenafil DMTBGW8 Major Increased risk of prolong QT interval by the combination of Thioridazine and Vardenafil. Sexual dysfunction [HA00-HA01] [52]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Thioridazine and LEE011. Solid tumour/cancer [2A00-2F9Z] [52]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Thioridazine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [52]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Thioridazine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [52]
Doxorubicin DMVP5YE Major Increased risk of prolong QT interval by the combination of Thioridazine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [52]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Thioridazine and Pitolisant. Somnolence [MG42] [52]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Thioridazine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [52]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Thioridazine and Lenvatinib. Thyroid cancer [2D10] [52]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Thioridazine and Cabozantinib. Thyroid cancer [2D10] [52]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Thioridazine and Papaverine. Tonus and reflex abnormality [MB47] [90]
Tizanidine DMR2IQ4 Major Increased risk of prolong QT interval by the combination of Thioridazine and Tizanidine. Tonus and reflex abnormality [MB47] [52]
Tacrolimus DMZ7XNQ Major Increased risk of prolong QT interval by the combination of Thioridazine and Tacrolimus. Transplant rejection [NE84] [52]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Thioridazine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [51]
Methdilazine DMAUHQX Major Increased risk of prolong QT interval by the combination of Thioridazine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [78]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Thioridazine and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [51]
Trimeprazine DMEMV9D Major Increased risk of prolong QT interval by the combination of Thioridazine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [78]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Thioridazine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [51]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Thioridazine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [55]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Thioridazine and Azatadine. Vasomotor/allergic rhinitis [CA08] [55]
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Thioridazine and Propafenone. Ventricular tachyarrhythmia [BC71] [52]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Thioridazine and Flecainide. Ventricular tachyarrhythmia [BC71] [52]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Thioridazine and Amiodarone. Ventricular tachyarrhythmia [BC71] [52]
⏷ Show the Full List of 248 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Carmellose sodium E00625 Not Available Disintegrant
Hydroxypropyl cellulose E00632 Not Available Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose E00634 Not Available Coating agent
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Thioridazine 10 mg tablet 10 mg Oral Tablet Oral
Thioridazine 100 mg tablet 100 mg Oral Tablet Oral
Thioridazine 25 mg tablet 25 mg Oral Tablet Oral
Thioridazine 50 mg tablet 50 mg Oral Tablet Oral
Thioridazine Hydrochloride 25mg tablet 25mg Tablet Oral
Thioridazine Hydrochloride 100mg tablet 100mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 100).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 088001.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4.
8 Models of drug treatment in the attention deficit disorder with hyperactivity. Rev Neurol. 2002 Feb;34 Suppl 1:S98-S106.
9 Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
10 Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol. 2003 May;59(1):45-50.
11 CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems. Antimicrob Agents Chemother. 2013 Nov;57(11):5448-56.
12 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
13 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
14 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
15 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
17 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
18 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
19 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
20 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
21 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
22 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
23 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
24 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
25 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
26 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
27 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
28 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
29 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
30 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
31 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
32 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
33 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
34 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
35 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
36 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
37 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
38 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
39 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
40 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
41 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
42 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
43 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
44 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
45 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
46 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
47 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
48 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
49 Johnson AL, Hollister LE, Berger PA "The anticholinergic intoxication syndrome: diagnosis and treatment." J Clin Psychiatry 42 (1981): 313-7. [PMID: 7251568]
50 Cerner Multum, Inc. "Australian Product Information.".
51 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
52 Canadian Pharmacists Association.
53 Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993): 89-95. [PMID: 8422746]
54 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
55 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
56 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
57 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
58 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
59 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
60 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
61 Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
62 Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
63 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
64 Multum Information Services, Inc. Expert Review Panel.
65 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
66 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
67 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
68 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
69 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
70 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
71 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
72 Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62. [PMID: 14197995]
73 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
74 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
75 Carrillo JA, Ramos SI, Herraiz AG, Llerena A, Agundez JAG, Berecz R, Duran M, Benitez J "Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients." J Clin Psychopharmacol 19 (1999): 494-9. [PMID: 10587283]
76 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
77 Fletcher GF, Kazamias TM "Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias." Am Heart J 78 (1969): 135-8. [PMID: 5794785]
78 El-Yousef MK, Manier DH "Tricyclic antidepressants and phenothiazines." JAMA 229 (1974): 1419. [PMID: 4152942]
79 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
80 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
81 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
82 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
83 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
84 Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
85 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
86 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
87 Product Information. Norprolac (quinagolide). Ferring Inc, North York, IA.
88 Warnes H, Lehmann HE, Ban TA "Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases." Can Med Assoc J 96 (1967): 1112-3. [PMID: 6021058]
89 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
90 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]